CO2020007275A2 - Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas - Google Patents

Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas

Info

Publication number
CO2020007275A2
CO2020007275A2 CONC2020/0007275A CO2020007275A CO2020007275A2 CO 2020007275 A2 CO2020007275 A2 CO 2020007275A2 CO 2020007275 A CO2020007275 A CO 2020007275A CO 2020007275 A2 CO2020007275 A2 CO 2020007275A2
Authority
CO
Colombia
Prior art keywords
mobilization
compositions
donor
progenitor cells
hematopoietic stem
Prior art date
Application number
CONC2020/0007275A
Other languages
English (en)
Inventor
Dwight Morrow
Patrick C Falahee
Anthony Boitano
Michael P Cooke
Kevin A Goncalves
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/834,017 external-priority patent/US10058573B1/en
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of CO2020007275A2 publication Critical patent/CO2020007275A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)

Abstract

La invención proporciona composiciones y métodos útiles para movilizar poblaciones de células madre y progenitoras hematopoyéticas dentro de un donante, así como para determinar si las muestras de células movilizadas son adecuadas para su liberación para la expansión ex vivo y/o para el uso terapéutico. De acuerdo con las composiciones y métodos descritos en el presente documento, las células madre y progenitoras hematopoyéticas movilizadas pueden extraerse de un donante y administrarse a un paciente para el tratamiento de diversos trastornos de células madre, incluyendo enfermedades hematopoyéticas, trastornos metabólicos, cánceres y enfermedades autoinmunitarias, entre otras. En ciertas realizaciones, las composiciones y métodos descritos en el presente documento conducen a la movilización de una población de células CD34dim que tienen efectos inmunosupresores y que pueden reducir la incidencia de la enfermedad de injerto contra huésped. 
CONC2020/0007275A 2017-12-06 2020-06-16 Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas CO2020007275A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15/834,017 US10058573B1 (en) 2017-12-06 2017-12-06 Dosing regimens for the mobilization of hematopoietic stem cells
US201762596056P 2017-12-07 2017-12-07
US16/101,676 US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells
US201862753656P 2018-10-31 2018-10-31
US201862773954P 2018-11-30 2018-11-30
PCT/US2018/064335 WO2019113375A2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Publications (1)

Publication Number Publication Date
CO2020007275A2 true CO2020007275A2 (es) 2020-07-31

Family

ID=66749948

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0007275A CO2020007275A2 (es) 2017-12-06 2020-06-16 Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas

Country Status (12)

Country Link
EP (1) EP3720494A2 (es)
JP (2) JP2021505172A (es)
KR (1) KR20200096942A (es)
CN (1) CN111712262A (es)
AU (1) AU2018378804A1 (es)
BR (1) BR112020011186A2 (es)
CA (1) CA3083783A1 (es)
CO (1) CO2020007275A2 (es)
IL (1) IL275077A (es)
MX (1) MX2020005878A (es)
SG (1) SG11202004913TA (es)
WO (1) WO2019113375A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2021087406A1 (en) * 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
EP4143302A1 (en) * 2020-04-27 2023-03-08 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) * 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6080398A (en) 1993-06-08 2000-06-27 Smithkline Beecham Corporation Truncated gro and KC chemokines having enhanced bioactivity
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
NZ332174A (en) 1997-02-11 1999-03-29 Mallinckrodt Chemical Inc Reactor and method for solid peptide synthesis
ATE525477T1 (de) 1998-03-30 2011-10-15 Northwest Biotherapeutics Inc Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
MXPA01009674A (es) 1999-03-24 2003-07-21 Anormed Inc Compuestos heterociclicos que se unen a receptores de quimiocina.
JP2003516984A (ja) 1999-12-17 2003-05-20 アノーメッド・インコーポレイテッド ケモカインレセプターを結合する複素環式化合物
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
JP5414958B2 (ja) 2000-06-05 2014-02-12 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク ヒト骨髄由来内皮前駆細胞の同定、及び虚血性傷害後の心筋細胞の機能を改善するためのヒト骨髄由来内皮前駆細胞の使用
MXPA04000982A (es) * 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
DE60236520D1 (de) 2001-08-16 2010-07-08 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US20070033666A1 (en) 2005-06-24 2007-02-08 Harris Reuben S Using cytosine deaminases to diminish retroelement transfer from pigs to humans
US20090221683A1 (en) * 2005-10-18 2009-09-03 Caritas St.Elizabeth Medical Center Of Boston, Inc Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis
EP2484758B1 (en) 2005-10-18 2013-10-02 Precision Biosciences Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
RU2009107030A (ru) * 2006-08-02 2010-09-10 Джензим Корпорейшн (Us) Комбинированная терапия
MX2009001445A (es) * 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.
EP1995316A1 (de) 2007-05-25 2008-11-26 Qiagen GmbH Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen
EP2009095A1 (en) 2007-06-28 2008-12-31 Innovalor AG Method of generating glucose-responsive cells
EP3098309B1 (en) 2007-10-31 2019-04-10 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2270025A1 (en) 2009-06-29 2011-01-05 Centre National pour la Recherche Scientifique (CNRS) Solid phase peptide synthesis of peptide alcohols
WO2011100505A2 (en) 2010-02-11 2011-08-18 Recombinetics, Inc. Methods and materials for producing transgenic artiodactyls
CA2828239C (en) 2011-02-25 2020-10-06 Recombinetics, Inc. Genetically modified animals and methods for making the same
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR20160023638A (ko) * 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 이동하기 위한 방법 및 조성물
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
WO2017147610A1 (en) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Also Published As

Publication number Publication date
IL275077A (en) 2020-07-30
MX2020005878A (es) 2020-10-07
JP2024023226A (ja) 2024-02-21
JP2021505172A (ja) 2021-02-18
KR20200096942A (ko) 2020-08-14
AU2018378804A1 (en) 2020-06-11
CN111712262A (zh) 2020-09-25
EP3720494A2 (en) 2020-10-14
CA3083783A1 (en) 2019-06-13
BR112020011186A2 (pt) 2020-11-17
WO2019113375A3 (en) 2019-07-18
WO2019113375A2 (en) 2019-06-13
SG11202004913TA (en) 2020-06-29

Similar Documents

Publication Publication Date Title
CO2020007275A2 (es) Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
CL2019003390A1 (es) Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer
CL2018003699A1 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva (divisional solicitud 201701110)
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
CO2020004906A2 (es) Composiciones y métodos para la eliminación de células cd117+
NI201100083A (es) Compuestos que expanden células madre hematopoyéticas.
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
WO2019084057A3 (en) Compositions and methods for the depletion of cd117+ cells
CU24043B1 (es) Hormona foliculoestimulante humana recombinante, composición farmacéutica que la comprende
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
UY38389A (es) Dispositivos implantables para terapia celular y métodos relacionados
BR112021021165A2 (pt) Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
CL2020003319A1 (es) Receptores del factor de crecimiento quiméricos
CO2021006259A2 (es) Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos
MX2021000954A (es) Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales.
CO2020006855A2 (es) Composiciones y métodos para el agotamiento de células cd2+
CL2019001014A1 (es) Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.
CO2022003156A2 (es) Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15rα y su uso
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
BR112018010066A8 (pt) Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo
MX2020005235A (es) Celula humana transformada y uso de la misma.
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos